Every 10-Q that GoHealth, Inc. (GOCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GOCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOCO filings page.
GoHealth, Inc. reports first-quarter 2026 net revenues of $11.9 million, down sharply from $221.0 million a year earlier, and a net loss of $66.1 million. The loss reflects much lower Medicare revenue and high operating costs, especially general and administrative expenses and interest on heavy debt.
Cash was $39.9 million as of March 31, 2026 against term loan facilities of $701.8 million, and management discloses substantial doubt about the company’s ability to continue as a going concern because of tightening minimum liquidity covenants. GoHealth is negotiating strategic alternatives with lenders while also facing ongoing False Claims Act litigation in which the Department of Justice has intervened.
GoHealth, Inc. reported a sharp downturn for the quarter ended September 30, 2025. Net revenues were $34,186 thousand, and the company recorded a net loss of $313,918 thousand, driven by $206,163 thousand in impairment charges on indefinite and long‑lived assets. Operating expenses climbed to $322,103 thousand, resulting in a loss from operations of $287,917 thousand.
Liquidity and leverage were central themes. GoHealth amended its credit facilities and entered a Superpriority Senior Secured Credit Agreement totaling $115.0 million (including $80.0 million new‑money and $35.0 million roll‑up term loans) and issued 4,766,219 Class A shares to lenders tied to Amendment No. 14. Long‑term debt (net) rose to $581,844 thousand, and the company ended the quarter with cash of $32,076 thousand. Nine‑month operating cash flow was an outflow of $82,873 thousand.
Management disclosed a significant likelihood of failing to maintain covenant compliance within 12 months absent mitigating actions, and initiated cost measures including a Q4 2025 workforce reduction of approximately 487 employees. As of November 6, 2025, shares outstanding were 16,093,116 Class A and 12,620,884 Class B.
GoHealth reported mixed results for the quarter ended June 30, 2025. Net revenues declined to $94.0 million from $105.9 million a year earlier, while year-to-date revenues increased to $315.0 million from $291.5 million. The company recorded a significant $53.0 million indefinite-lived trade names impairment that, together with higher operating expenses, drove an operating loss of $99.4 million for the quarter and a net loss attributable to GoHealth of $54.3 million (basic loss per Class A share $5.10).
Liquidity and capital structure changed materially: cash and cash equivalents were $35.6 million, total long-term debt rose to $560.0 million and commissions receivable remained substantial at $996.6 million. Management states that after entering a Superpriority Credit Agreement and amendments, management believes available liquidity is sufficient to cover operating requirements for the next 12 months, alleviating prior substantial doubt about going concern.